�Statins, a group of drugs used to turn down cholesterol levels in masses with or at risk of infection of having cardiovascular disease, should be used more than frequently to combat the adverse cardiovascular outcomes from atherosclerosis, according to fresh research published in the September 2008 issue of the Journal of Vascular Surgery. Atherosclerosis (hardening of the arteries) is the leading cause of death of adults worldwide and is caused when fat person substances collect in the inner liner of artery walls.
In a 10-year population-based study (from 1995 to 2005), of 343,154 elderly patients in Ontario, Canada, researchers discovered an important maintenance gap in the management of old patients with symptomatic coronary artery disease due to the suboptimal prescription of statins.
Sixty-nine pct of the patients had coronary artery disease (CAD), 34 percentage had cerebrovascular disease (CVD) and 7 percent had peripheral arterial disease (PAD). About 46 percent of the patients were women, and mean patient historic period was 77.1 years.
The percentage of all atherosclerotic patients wHO were treated with statins increased from 9.8 percent to 55.3 percent. When broken down by each condition, the percentages of patients disposed statins were as follows: those with CAD jumped 11.8 percent to 61.2 percent; patients with CVD increased from 5.3 percent to 41.2 percent; and those with PAD rose from 6.8 percentage to 43.3 percent.
"Even though the use of statin therapy in elderly patients with symptomatic coronary artery disease has increased substantially during the past times decade, our study showed many patients remain untreated," said Subodh Verma, MD, PhD, a cardiac surgeon at St. Michael's Hospital, University of Toronto and the Canada Research Chair in Atherosclerosis. He added that suboptimal use was greatest among patients with PAD or CVD, or both, and lowest in patients with CAD.
Given the heightened risk of cardiovascular adverse outcomes in patients with atherosclerosis, researchers believe their results have crucial and immediate implications. "This was specially evident in patients with CVD and PAD with data from January to March in 2004, that indicated that less than 50 per centum of these patients were on statins," said Dr. Verma.
Strong evidence supports the management of atherosclerosis with statins, according to Dr. Verma. He pointed to a recent study involving more than 90,000 participants that indicated for every fragile reduction (1 millimole per litre) in low-density lipoprotein (LDL) cholesterol, there was also step-down of around 23 pct in the risk of heart attacks or coronary-related mortality, a 24 percent reduction in the indigence for coronary revascularization, and a 17 percent simplification in the rate of fatal or non-fatal stroke.
Co-investigator Mohammed Al-Omran, MD, MSc, an help professor in the Division of Vascular Surgery, King Saudi University, Riyadh, Saudi Arabia and a scientist at St. Michael's Hospital, University of Toronto, famous that the results of the stream study support current literature and underscore the inequities in the use of risk reduction therapies for patients with PAD compared with patients with CAD.
"Our findings high spot the intervention care gaps in patients with coronary artery disease and crataegus oxycantha be useful for guiding medical interventions, focusing continuing medical education programs, encouraging active discussions on peril reduction therapies at scientific meetings, and other educational outreach programs that place to bring physicians' practice into agreement with stream guidelines for cardiovascular risk of infection reduction," added Dr. Al-Omran.
About Journal of Vascular Surgery
Journal of Vascular Surgery provides vascular, cardiothoracic and general surgeons with the well-nigh recent info in vascular surgery. Original, peer-reviewed articles cover clinical and data-based studies, noninvasive diagnostic techniques, processes and vascular substitutes, microvascular operative techniques, angiography and endovascular management. Special issues release papers presented at the annual get together of the Journal's sponsoring society, the Society for Vascular Surgery. Visit the Journal Web site.
About the Society for Vascular Surgery
The Society for Vascular Surgery (SVS) is a not-for-profit medical society that seeks to advance excellence and invention in vascular health through education, protagonism, research and public consciousness. SVS is the home advocate for 2,600 vascular surgeons dedicated to the prevention and cure of vascular disease.
Society for Vascular Surgery
633 N St. Clair, 24th Fl.
Chicago, IL 60611
United States
http://www.jvascsurg.org
More info
Sunday, 7 September 2008
Subscribe to:
Posts (Atom)